In the bustling landscape of biopharmaceutical advancement, innovation is the currency, and at the 17th PEGS Europe Protein & Antibody Engineering Summit, Creative Biolabs didn’t just set up a booth; they orchestrated a symphony of cutting-edge technology. The event served as a stage for Creative Biolabs to unveil a tapestry of updates in antibody discovery, production, and optimization, igniting discussions on pivotal topics in Contract Development and Manufacturing Organization (CDMO) services.
Antibody CDMO—Empowering Innovation through Integration
Transitioning an antibody drug from concept to clinic is a journey fraught with challenges, where maintaining control over execution is paramount. Creative Biolabs’ antibody CDMO solutions serve as an “All-in-One Workshop,” guiding developers seamlessly from DNA inception to current Good Manufacturing Practices (cGMP) compliance. By offering an integrated approach that prevents the fragmentation often associated with outsourcing, Creative Biolabs aims to empower clients with a collaborative environment. An industry expert remarked, “Clients are seeking manufacturers who provide integrated, responsive solutions. It’s no longer just about transactions; it’s about co-creation. We are constructing safe and efficient expressways for innovative molecules.”
Encompassing scales ranging from 2 liters to 2,000 liters, accommodating various formats such as monoclonal antibodies (mAbs), bispecific antibodies (BsAbs), and antibody-drug conjugates (ADCs), and facilitating the completion of all developmental stages within a coherent sequence, Creative Biolabs’ integrated systems for co-creation epitomize efficiency and innovation.
Recombinant Antibody Engineering—Crafting Precision in Protein Design
The realm of recombinant antibody engineering offered by Creative Biolabs transforms antibodies into meticulously designed building blocks, be it humanized, fragmented, single-domain, or bispecific. Each variant is tailored with biological precision, elevating production processes from mere manufacturing to molecular craftsmanship. By predicting the residues that influence affinity and mutations that enhance stability, Creative Biolabs fine-tunes antibodies to enhance their success rate across the development pipeline.
OmicsAb™ Platform—Defying Temporal Constraints with High-Throughput Capabilities
The OmicsAb™ high-throughput antibody production platform emerged as a time-bending marvel at PEGS Europe, transcending the boundaries of conventional 96-well expression systems. This platform enables automated cloning, expression, and purification, expediting the production and screening of candidate antibodies. A spokesperson enthused, “Within days, we can express and purify hundreds of potential antibodies. This disruptive technology accelerates the screening process, transforming it into a precision and efficiency race.” Compatible with diverse host systems like Chinese hamster ovary (CHO) and Human Embryonic Kidney 293 (HEK293) cells, the OmicsAb platform empowers biopharma developers to streamline cross-system testing, thereby enhancing early-stage decision-making and aligning with the rapid pace of biopharmaceutical innovation.
“PEGS Europe serves not just as an exhibition but as a reflection of industry challenges and our untapped potential. Our mission is to render complex technologies manageable, reproducible, and scalable.”
In its pursuit of advancing bispecific antibodies, Fc-fusion proteins, antibody-drug conjugates (ADCs), and leveraging AI-driven design and high-throughput screening, Creative Biolabs continues to push the boundaries of next-generation biotherapeutics manufacturing.
Takeaways:
– Creative Biolabs’ integrated systems for co-creation in antibody CDMO offer a seamless pathway from concept to clinic, fostering innovation and control.
– The precision-driven recombinant antibody engineering by Creative Biolabs elevates protein design to a realm of molecular craftsmanship, enhancing success rates in the development pipeline.
– The OmicsAb™ high-throughput platform defies temporal constraints, enabling rapid antibody production, screening, and purification, aligning with the accelerated pace of biopharmaceutical innovation.
Tags: biopharma, process development
Read more on news.marketersmedia.com